Protagonist Therapeutics Inc (PTGX)

12:22 PM

Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025 - Springfield News-Leader

12:22 PM

10:15 AM

Sentiment analysis tools applied to Protagonist Therapeutics Inc.2025 Trading Volume Trends & Daily Stock Trend Watchlist - newser.com

10:15 AM

09:50 AM

Why Protagonist Therapeutics Inc. stock could be next big winner2025 Analyst Calls & Growth Oriented Trading Recommendations - newser.com

09:50 AM

07:50 AM

Can Protagonist Therapeutics Inc. stock hit record highs againJuly 2025 Breakouts & AI Optimized Trade Strategies - newser.com

07:50 AM

06:25 AM

Short interest data insights for Protagonist Therapeutics Inc.M&A Rumor & High Accuracy Swing Trade Signals - newser.com

06:25 AM

Sep 30, 2025

Historical volatility pattern of Protagonist Therapeutics Inc. visualizedLong Setup & Real-Time Buy Signal Notifications - newser.com

Sep 30, 2025

Sep 29, 2025

Protagonist Therapeutics (NASDAQ:PTGX) Shares Down 5.1%What's Next? - MarketBeat

Sep 29, 2025

Sep 29, 2025

Protagonist Therapeutics Hits New 52-Week High of $68.26, Up 103% - Markets Mojo

Sep 29, 2025

Sep 29, 2025

Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025 - Corpus Christi Caller-Times

Sep 29, 2025

Sep 28, 2025

What analysts say about Protagonist Therapeutics Inc stockGlobal Market Influence & Free Discover Massive Upside Stocks - earlytimes.in

Sep 28, 2025

Sep 27, 2025

What drives Protagonist Therapeutics Inc stock priceMarket Liquidity Analysis & Market Monitoring and Alerts - earlytimes.in

Sep 27, 2025

Sep 26, 2025

Protagonist Therapeutics (MEX:PTGX) Tariff Resilience Score : 5/10 (As of Sep. 27, 2025) - GuruFocus

Sep 26, 2025

Sep 26, 2025

Protagonist Therapeutics stock reaches all-time high at 66.7 USD - Investing.com India

Sep 26, 2025

Sep 26, 2025

Protagonist Therapeutics stock reaches all-time high at 66.7 USD By Investing.com - Investing.com Canada

Sep 26, 2025

Sep 25, 2025

Protagonist Therapeutics Hits New 52-Week High of $66.70, Up 98.82% - Markets Mojo

Sep 25, 2025

Sep 25, 2025

7,530 Shares in Protagonist Therapeutics, Inc. $PTGX Acquired by Palumbo Wealth Management LLC - MarketBeat

Sep 25, 2025

Sep 25, 2025

Protagonist Therapeutics Hits New 52-Week High of $65.08 - Markets Mojo

Sep 25, 2025

Sep 25, 2025

Assenagon Asset Management S.A. Increases Stock Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat

Sep 25, 2025

Sep 24, 2025

Insider Sell: William Waddill Sells 4,000 Shares of Protagonist Therapeutics Inc (PTGX) - GuruFocus

Sep 24, 2025

Sep 24, 2025

Protagonist Therapeutics (NASDAQ:PTGX) Director Sells $257,000.00 in Stock - MarketBeat

Sep 24, 2025

Sep 24, 2025

Waddill, Protagonist Therapeutics director, sells $257k in shares By Investing.com - Investing.com Canada

Sep 24, 2025

Sep 24, 2025

Protagonist Therapeutics (NASDAQ:PTGX) Reaches New 12-Month HighShould You Buy? - MarketBeat

Sep 24, 2025

Sep 24, 2025

Protagonist Therapeutics Hits New 52-Week High of $64.59, Up 94.48% - Markets Mojo

Sep 24, 2025

Sep 23, 2025

Protagonist Therapeutics, Inc. $PTGX Shares Acquired by Exchange Traded Concepts LLC - MarketBeat

Sep 23, 2025

Sep 23, 2025

Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress - Cincinnati Enquirer

Sep 23, 2025

Sep 23, 2025

Voya Investment Management LLC Has $2.89 Million Stake in Protagonist Therapeutics, Inc. $PTGX - MarketBeat

Sep 23, 2025

Sep 23, 2025

Strs Ohio Takes $919,000 Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat

Sep 23, 2025

Sep 23, 2025

Protagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to the European Medicines Agency - Lubbock Avalanche-Journal

Sep 23, 2025

Sep 23, 2025

Protagonist Therapeutics (NASDAQ:PTGX) Sets New 12-Month HighHere's Why - MarketBeat

Sep 23, 2025

Sep 22, 2025

Protagonist Therapeutics (NASDAQ:PTGX) Coverage Initiated at Barclays - MarketBeat

Sep 22, 2025

Sep 22, 2025

Protagonist Therapeutics Hits New 52-Week High of $63.30 - Markets Mojo

Sep 22, 2025

Sep 22, 2025

Analysts Set Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Target Price at $68.08 - MarketBeat

Sep 22, 2025

Sep 22, 2025

Protagonist Therapeutics' (PTGX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat

Sep 22, 2025

Sep 21, 2025

Protagonist Therapeutics (NASDAQ:PTGX) Coverage Initiated by Analysts at Barclays - MarketBeat

Sep 21, 2025

Sep 20, 2025

Protagonist Therapeutics Hits New 52-Week High at $62.21 - Markets Mojo

Sep 20, 2025

Sep 20, 2025

Aug Big Picture: Will Protagonist Therapeutics Inc benefit from AI trendsMarket Volume Summary & Precise Entry and Exit Recommendations - khodrobank.com

Sep 20, 2025